Shots:

• The P-IIb Study 201 trial evaluates the efficacy of lecanemab vs PBO  in 856 patients with MCI due to AD and mild AD
• The results showed robust clearance of brain amyloid and demonstrated clinical decline across multiple clinical and biomarker EPs. Additionally, the therapy showed consistent treatment effect across multiple statistical methods @18mos. for ADCOMS, CDR-SB, and ADAS-Cog14.
• Lecanemab is currently being evaluated in the P-III AHEAD 3-45 study in patients with preclinical AD, based on the P-II Study 201 study. A pre-specified analysis of Study 201 study demonstrated reduction of brain Aß accumulation & slowing of disease progression in early AD

  Ref: Biogen | Image: Pharmaletter